News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Commentaries
Subscribe

Spotlight -

Our June 2026 print issue|

Free Webinar: The Great 340B Debate|

2026 ASCO Annual Meeting|

2026 State of Pharmacy survey results available now

Opinion|Videos|August 7, 2024

Impact of Myelofibrosis on Quality of Life: Key Clinical Features

Author(s)Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

An expert on myelofibrosis provides clinical insights on features of the disease that can impact patient quality of life, including splenomegaly, hypertension, and bone pain.

Episodes in this series

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 1 Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 2 Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 3 Impact of Myelofibrosis on Quality of Life: Key Clinical Features

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 4 Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 5 JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 6 Key Patient Factors Guiding Myelofibrosis Treatment Selection

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 7 Key Outcomes for Monitoring Myelofibrosis Treatment Response

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 8 Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 9 Understanding Financial Toxicity in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 10 Advancing Myelofibrosis Treatment: What Lies Ahead

EP. 11 K-Cast Written Summary. Optimizing the Management of Myelofibrosis

EP. 11 K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following question:

What are some of the clinical features of the disease that impact greatest on patient quality of life?

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

Key Takeaways for AD Management

ByMatthew Zirwas, M.D.

April 9th 2025

Integrating New AD Therapies Into Clinical Practice

ByMatthew Zirwas, M.D.

April 9th 2025

Recent Advancements in AD Treatment

ByMatthew Zirwas, M.D.

April 2nd 2025

Overcoming Barriers to Treatment in AD

ByMatthew Zirwas, M.D.

April 2nd 2025

Shared Decision-Making in AD Management

ByMatthew Zirwas, M.D.

March 26th 2025

Latest CME

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

July 14, 2026

27th Annual International Lung Cancer Congress®

In-Person Event

27th Annual International Lung Cancer Congress®

July 24-25, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Luis Paz-Ares, MD, PhD; Jacob Sands, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on Managed Healthcare Executive

Health insurance without a net(work)

Medicare's HIV care costs projected to nearly triple by 2035, study shows

The LOE cliff

The health insurance teeter-totter

Nearly 40% of insulin users pay more than $150 a month